EGFR and non-small cell lung carcinoma: The Chinese clinical trial of RECEL involving 41 unresectable stage III NSCLC patients combined with EGFR mutations in exon 19 or 21 compared PFS as the primary outcome between erlotinib group (n=20) and EP group (n=21) (12).